Physician

Nashat Gabrail, M.D.

According to 2025 Medicare claims, Nashat Gabrail, M.D. (NPI: 1104854751) practices hematology/oncology in the Canton-Massillon, OH market, with the plurality of this provider's patient population coming from Stark, OH. This provider's primary affiliated billing organization is NASHAT Y GABRAIL MD INC (NPI: 1346219466; TIN: 341769608) and primary practice location at 44718-2566. Gabrail is affiliated with the IHC Quality Partners, LLC (ACO ID: A2833), participating under the MSSP model.

Gabrail's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 147 traditional Medicare patients, billed 97,060 HCPCS/CPT codes, and received $1,344,313 in Medicare payments. The top billing code was 80053 (Blood test, comprehensive group of blood chemicals). Part D data shows 1,711 prescription claims across 166 beneficiaries totaling $4,721,596 in drug costs, led by Ocrevus (Ocrelizumab). 2022 DME data shows 11 claims. Open Payments data shows 383 records totaling $1,293,748. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing did not follow a clear longitudinal pattern. Concurrently, Part D prescription costs have moved from a lower plateau to a higher plateau, from $1,615,779 to $4,721,596. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $5,758 to $450.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	275	191,997	$1,496,865
2016	291	243,191	$2,487,335
2017	282	211,245	$2,241,438
2018	219	146,614	$2,088,748
2019	207	151,342	$1,992,087
2020	242	140,874	$2,400,551
2021	351	141,385	$2,124,756
2022	168	95,987	$1,875,573
2023	148	92,226	$1,753,649
2024	147	97,060	$1,344,313

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	205	2,066	$1,615,779
2016	212	2,255	$2,470,919
2017	190	2,368	$2,731,390
2018	163	2,396	$3,224,047
2019	178	2,527	$4,866,955
2020	166	2,138	$5,489,231
2021	142	1,772	$4,554,336
2022	166	1,698	$3,150,050
2023	169	1,577	$3,847,784
2024	166	1,711	$4,721,596

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	89	$6,488
2016	N/R	124	$6,227
2017	N/R	102	$4,733
2018	N/R	43	$1,388
2019	N/R	32	$1,044
2020	N/R	N/R	N/R
2021	N/R	13	$1,126
2022	N/R	11	$1,003
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
80053	Blood test, comprehensive group of blood chemicals	102	411	$10
82575	Creatinine clearance measurement to test for kidney function	102	402	$9
36415	Insertion of needle into vein for collection of blood sample	102	461	$8
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	105	536	$8
83735	Magnesium level	102	413	$7

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Ocrevus	Ocrelizumab	23	4,140	$900,712
Ibrance	Palbociclib	55	1,540	$859,099
Inrebic	Fedratinib Dihydrochloride	13	390	$344,460
Revlimid	Lenalidomide	18	504	$314,431
Doptelet	Avatrombopag Maleate	24	804	$296,616

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	59	$37,083	SOBI, INC
Research Payments	Reported research-related payment or transfer-of-value amount.	324	$1,256,665	Epizyme, Inc.
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Nashat Gabrail, M.D.?

Tedicare shows public-source Medicare data for Nashat Gabrail, M.D. (NPI 1104854751), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Nashat Gabrail, M.D. have ACO affiliation data?

Nashat Gabrail, M.D. is shown with ACO affiliation data for IHC Quality Partners, LLC (MSSP, ACO ID A2833).

What billing organization is linked to Nashat Gabrail, M.D.?

Nashat Gabrail, M.D. is linked to NASHAT Y GABRAIL MD INC (billing NPI 1346219466) in the available physician profile data.

Does Nashat Gabrail, M.D. have Open Payments data?

Nashat Gabrail, M.D. has 383 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.